Novartis expands targeted radioligand therapy pipeline with in-license for compounds targeting Fibroblast Activation Protein (FAP)

- Park JE, Lenter MC, Zimmermann RN, Garin-Chesa P, Old LJ, Rettig WJ. Fibroblast activation protein, a dual specificity serine protease expressed in reactive human tumor stromal fibroblasts. J Biol Chem. 1999;274(51):36505-12.
- Loktev A, Lindner T, Burger EM, et al. Development of Fibroblast Activation Protein?Targeted Radiotracers with Improved Tumor Retention. J Nucl Med 2019; 60:1421?1429. doi 10.2967/jnumed.118.224469.
- Kratochwil C, Flechsig P, Lindner T, et al.?68Ga-FAPI PET/CT: Tracer Uptake in 28 Different Kinds of Cancer. J Nucl Med 2019; 60:801?805. doi: 10.2967/jnumed.119.227967.
- Rettig WJ, Garin-Chesa P, Healey JH, et al. Regulation and Heteromeric Structure of the Fibroblast Activation Protein in Normal and Transformed Cells of Mesenchymal and Neuroectodermal Origin. Cancer Res. 1993;53:3327?3335.
- Lidner T, Loktev A, Altmann A, et al. Development of quinoline based theranostic ligands for the targeting of fibroblast activation protein. J Nucl Med 2018 Sep;59(9):1415-1422. doi:10.2967/jnumed.118.210443.
- Liao L, Ni Y, He R, et al. Clinical implications of fibroblast activation protein-a in non-small cell lung cancer after curative resection:a new predictor for prognosis. J Cancer Res Clin Oncol. 2013;139:1523?1528. doi: 10.1007/s00432-013-1471-8.
- Saigusa S, Toiyama Y, Tanaka K, et al. Cancer-associated fibroblasts correlate with poor prognosis in rectal cancer after chemoradiotherapy. Int J Oncol 2011;38: 655-663. doi: 10.3892/ijo.2011.906.
# # #
Novartis Media Relations E-mail:?media.relations@novartis.comAnja von Treskow Novartis Strategy & Financial Communications +41 79 392 8697 Anja.von_treskow@novartis.com Julie Masow Novartis US External Engagement +1 862 579 8456 Julie.masow@novartis.com | Rachel Levine Advanced Accelerator Applications, a Novartis company Communications +1 917 375 2935 Rachel.levine@novartis.com |
Central | North America | ||
Samir Shah | +41 61 324 7944 | Sloan Simpson | +1 862 778 5052 |
Thomas Hungerbuehler Isabella Zinck | +41 61 324 8425 +41 61 324 7188 |